A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 480 participants.

Also called NCT07693777

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 480 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07693777
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07693777. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-17 (anticipated); primary completion 2029-02-14 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
Condition
Severe Hypertriglyceridemia (sHTG)
Condition
Hypertriglyceridemia
Intervention (Biological)
DR10624 Injection
Intervention (Other)
Matching Placebo for DR10624
Lead sponsor
Zhejiang Doer Biologics Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07693777
Content hash
cb899d130b83131b4fb635a8e241661858d0c1c999179d05fc44084784c565df